UCB's Global Corporate Website

This section is intended for media and financial analysts

Luc Missorten has decided to pursue new opportunities

Brussels (Belgium), 2 July 2007 at 7:00 AM (CET) - UCB announces that Luc Missorten, Executive Vice President and Chief Financial Officer of UCB, will leave UCB on 1 September 2007. The name of his successor will be announced before that date and an orderly handover will be ensured.

Roch Doliveux, Chief Executive Officer of UCB commented, "I would like to pay particular tribute to Luc Missorten. Luc built and led a high performing team of finance professionals. He was also instrumental in the integration of Celltech and the acquisition of Schwarz Pharma. We thank him for his important contribution to the transformation of UCB and wish him every success in his new endeavours."

Luc Missorten joined UCB in February 2004 as General Manager of UCB Pharma Spain and was appointed Chief Financial Officer in November 2004. Before Luc Missorten joined UCB, he served as Chief Financial Officer of Interbrew (now InBev) and started his career at Citibank. He is also a member of the Board of Directors and Chairman of the Audit Committee of the Vandemoortele Group.



About UCB

UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing more than 8,500 people in over 40 countries, UCB achieved revenue of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange and owns 87.6% of Schwarz Pharma.


For further enquiries, please contact

Jean-Christophe Donck

Tel. +32 2 559 9346

Asset Download

Stay up-to-date on the latest news and information from UCB